Personalized cell therapy is based on patient genome. It provides accurate diagnosis of the diseases and allows early detection of diseases at molecular level which in turn helps to reduce the side effects while minimizing the cost of the treatment.
The global personalized cell therapy market report has been segmented on the basis of technique, therapeutic area, and region. Changing lifestyle and increasing prevalence of chronic disease such as diabetes, cancer, neurological disorders is expected to drive the market growth over the forecast period. Continuous innovations by manufacturers for personalized cell therapy products and rising government funding for research and development is another factor expected to propel the growth of global personalized cell therapy market over the forecast period.
Therapeutic area segment includes cardiovascular diseases, neurological disorders, inflammatory diseases, diabetes, and cancer. The cancer segment of global personalized cell therapy market is expected to witness rapid growth rate owing to increasing prevalence of cancer globally. In 2016, for instance National Cancer Institute had estimated that 1,685,210 new cases of cancer will be diagnosed in US. The number of new cases of cancer is 454.8 per 100,000 men and women per year.
Do Inquiry of the Report Here: https://marketresearch.biz/report/personalized-cell-therapy-market/#inquiry
Regional segmentation includes North America, Europe, Latin America, Asia Pacific and Middle East and Africa. North America contributes major market share and expected to maintain its dominance over the forecast period owing to increasing government initiatives for research and development in the region. Asia Pacific region is expected to witness rapid growth rate over the forecast period. Countries like India, China, is expected to support the growth of Asia Pacific, owing to the improving healthcare infrastructure and increasing prevalence of chronic diseases in the region.
Some prominent players in the global personalized cell therapy market are Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Oxford Nanopore Technologies, Cell Medica Ltd., MediGene AG, and TxCell